146 related articles for article (PubMed ID: 27150868)
41. An α-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
Eguchi K; Komori T; Saito T; Hoshide S; Kario K
J Electrocardiol; 2018; 51(1):21-26. PubMed ID: 28918212
[TBL] [Abstract][Full Text] [Related]
42. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
43. Late postprandial hypoglycemia due to bioactive insulin dissociation from autoantibody leading to unconsciousness in a patient with insulin autoimmune syndrome.
Nasu T; Suzuki R; Okamoto Y; Miyata K; Uno A; Nakao R; Kawashima A; Nakao T; Kondo M
Intern Med; 2011; 50(4):339-43. PubMed ID: 21325768
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Singh KP; Periyandavar I; Rajadhyaksha GC; Jayaram S; Mishra AB; Kinagi S; Sharma A; Baliga VP
J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
[TBL] [Abstract][Full Text] [Related]
46. [Seizures following Billroth II gastrectomy].
Harder J; Mikesch K; Mohr L; Blum HE
Dtsch Med Wochenschr; 2005 Mar; 130(11):574-6. PubMed ID: 15761785
[TBL] [Abstract][Full Text] [Related]
47. Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Uzu T; Yokoyama H; Itoh H; Koya D; Nakagawa A; Nishizawa M; Maegawa H; Yokomaku Y; Araki S; Abiko A; Haneda M
Clin Exp Nephrol; 2011 Feb; 15(1):58-63. PubMed ID: 20824296
[TBL] [Abstract][Full Text] [Related]
48. Usefulness of Continuous Glucose Monitoring for Prevention and Early Detection of Hypoglycemia Caused by a Ketogenic Diet and Late Dumping Syndrome.
Morikawa M; Hara Y; Nakazawa Y; Inaba Y; Motobayashi M
Pediatr Neurol; 2020 Apr; 105():65-66. PubMed ID: 32029333
[No Abstract] [Full Text] [Related]
49. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet.
Kellogg TA; Bantle JP; Leslie DB; Redmond JB; Slusarek B; Swan T; Buchwald H; Ikramuddin S
Surg Obes Relat Dis; 2008; 4(4):492-9. PubMed ID: 18656831
[TBL] [Abstract][Full Text] [Related]
50. [Impaired glucose tolerance in dumping syndrome].
Itoh H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():295-9. PubMed ID: 15779391
[No Abstract] [Full Text] [Related]
51. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
52. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
53. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Willms B; Lübke D; Ahrens K; Arends J
Schweiz Med Wochenschr; 1991 Sep; 121(38):1379-82. PubMed ID: 1656521
[TBL] [Abstract][Full Text] [Related]
54. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
55. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
[TBL] [Abstract][Full Text] [Related]
56. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Kishimoto M; Noda M
Clin Drug Investig; 2015 Feb; 35(2):141-7. PubMed ID: 25511640
[TBL] [Abstract][Full Text] [Related]
57. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
[TBL] [Abstract][Full Text] [Related]
58. [Studies on the relation between late dumping syndrome and glucagon responses to glucose].
Matsui T
Nihon Heikatsukin Gakkai Zasshi; 1988 Jun; 24(3):159-70. PubMed ID: 3073247
[TBL] [Abstract][Full Text] [Related]
59. Seven-day subcutaneous continuous glucose monitoring demonstrates that treatment with acarbose attenuates late dumping syndrome in a woman with gastrectomy for gastric cancer.
Buscemi S; Mattina A; Genova G; Genova P; Nardi E; Costanzo M
Diabetes Res Clin Pract; 2013 Jan; 99(1):e1-2. PubMed ID: 23146372
[No Abstract] [Full Text] [Related]
60. An uncommon cause of hypoglycemia: insulin autoimmune syndrome.
Savas-Erdeve S; Yılmaz Agladioglu S; Onder A; Peltek Kendirci HN; Bas VN; Sagsak E; Cetinkaya S; Aycan Z
Horm Res Paediatr; 2014; 82(4):278-82. PubMed ID: 25060673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
